65 related articles for article (PubMed ID: 38602501)
21. Anaplastic thyroid cancer: genome-based search for new targeted therapy options.
Hescheler DA; Hartmann MJM; Riemann B; Michel M; Bruns CJ; Alakus H; Chiapponi C
Endocr Connect; 2022 Apr; 11(4):. PubMed ID: 35275096
[TBL] [Abstract][Full Text] [Related]
22. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.
Cameselle-García S; Abdulkader-Sande S; Sánchez-Ares M; Rodríguez-Carnero G; Garcia-Gómez J; Gude-Sampedro F; Abdulkader-Nallib I; Cameselle-Teijeiro JM
Oncol Lett; 2021 Jul; 22(1):553. PubMed ID: 34093774
[TBL] [Abstract][Full Text] [Related]
24. Pathologic Features Associated With Molecular Subtypes of Well-Differentiated Thyroid Cancer.
Tang AL; Kloos RT; Aunins B; Holm TM; Roth MY; Yeh MW; Randolph GW; Tabangin ME; Altaye M; Steward DL
Endocr Pract; 2021 Mar; 27(3):206-211. PubMed ID: 33655886
[TBL] [Abstract][Full Text] [Related]
25. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
26. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.
Maniakas A; Dadu R; Busaidy NL; Wang JR; Ferrarotto R; Lu C; Williams MD; Gunn GB; Hofmann MC; Cote G; Sperling J; Gross ND; Sturgis EM; Goepfert RP; Lai SY; Cabanillas ME; Zafereo M
JAMA Oncol; 2020 Sep; 6(9):1397-1404. PubMed ID: 32761153
[TBL] [Abstract][Full Text] [Related]
27. Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.
Ragazzi M; Torricelli F; Donati B; Ciarrocchi A; de Biase D; Tallini G; Zanetti E; Bisagni A; Kuhn E; Giordano D; Frasoldati A; Piana S
Virchows Arch; 2021 Feb; 478(2):265-281. PubMed ID: 32683537
[TBL] [Abstract][Full Text] [Related]
28. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
29. PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Capdevila J; Wirth LJ; Ernst T; Ponce Aix S; Lin CC; Ramlau R; Butler MO; Delord JP; Gelderblom H; Ascierto PA; Fasolo A; Führer D; Hütter-Krönke ML; Forde PM; Wrona A; Santoro A; Sadow PM; Szpakowski S; Wu H; Bostel G; Faris J; Cameron S; Varga A; Taylor M
J Clin Oncol; 2020 Aug; 38(23):2620-2627. PubMed ID: 32364844
[TBL] [Abstract][Full Text] [Related]
30. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
31. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
32. Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Capdevila J; Mayor R; Mancuso FM; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J
Ann Oncol; 2018 Jun; 29(6):1454-1460. PubMed ID: 29648575
[TBL] [Abstract][Full Text] [Related]
33. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Oishi N; Kondo T; Ebina A; Sato Y; Akaishi J; Hino R; Yamamoto N; Mochizuki K; Nakazawa T; Yokomichi H; Ito K; Ishikawa Y; Katoh R
Mod Pathol; 2017 Nov; 30(11):1527-1537. PubMed ID: 28731042
[TBL] [Abstract][Full Text] [Related]
34. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract][Full Text] [Related]
35. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
37. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
38. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
39. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
[TBL] [Abstract][Full Text] [Related]
40. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
